Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractCellular senescence, a state of stable growth arrest, can occur in response to various stress stimuli such as telomere shortening, treatment with chemotherapeutic drugs or the aberrant activation of oncogenes. Senescent cells communicate with their environment by secreting various cytokines and growth factors, and it has become clear that this 'secretory phenotype' can have pro- as well as anti-tumorigenic effects. Recent work from our laboratory showed that premalignant, senescent hepatocytes are recognized and cleared through an antigen-specific immune response and that this immune response, designated as 'senescence surveillance' is crucial for tumor suppression in the liver [(Kang,T.W. et al. (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 479, 547-551]. It is an emerging concept that immune responses against senescent cells have a broader biological significance in cancer- as well as non-cancer pathologies and current data suggest that distinct immune responses are engaged to clear senescent cells in different disease settings. In this review article, we will discuss different examples how immune responses against senescent cells are involved to restrict disease progression in cancer- and non-cancer pathologies.
CitationImmune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies. 2012, 33 (6):1123-6 Carcinogenesis
AffiliationHelmholtz Centre for Infection Research, Braunschweig, Germany.
The following license files are associated with this item:
- Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.
- Authors: Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L
- Issue date: 2011 Nov 9
- Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells.
- Authors: Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Díaz Flaqué MC, Beguelin W, Frahm I, Charreau EH, Cassataro J, Elizalde PV, Schillaci R
- Issue date: 2012 Aug 1
- Immunosurveillance of senescent cells: the bright side of the senescence program.
- Authors: Sagiv A, Krizhanovsky V
- Issue date: 2013 Dec
- Senescent cells: SASPected drivers of age-related pathologies.
- Authors: Ovadya Y, Krizhanovsky V
- Issue date: 2014 Dec
- Cancer, aging and cellular senescence.
- Authors: Campisi J
- Issue date: 2000 Jan-Feb